Here's What Analysts Are Forecasting For Bio-Rad Laboratories, Inc. (NYSE:BIO) After Its First-Quarter Results
Yahoo Finance · 2 weeks ago
Open | 288.92 |
High | 291.57 |
Low | 290.23 |
Mkt Cap | 8.27B |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 289.45 |
52 Wk. Low | 261.59 |
52 Wk. High | 431.79 |
Related stocks
Bio Technology Firm
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 610.82M | 9.80% ▼ |
Net Income | 383.92M | 456.70% ▲ |
Diluted EPS | 2.29 | 479.70% ▲ |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $1.93 | - |
Q1 2024 | $2.15 | $2.29 |
Q4 2023 | $2.82 | $3.10 |
S&P 500^GSPC | 5,321.27-0.14 (-0.00%) |
Dow 30^DJI | 39,859.95-13.04 (-0.03%) |
Nasdaq^IXIC | 16,846.66+14.03 (+0.08%) |
142.09-8.79% | |
948.51-0.56% | |
Tesla, Inc.TSLA | 182.63-2.12% |